1. Catalog
  2. ORN - Hot Topics in Addiction Medicine - Spring 20 ...
Image For Activity Cover
ORN - Hot Topics in Addiction Medicine - Spring 2022 Webinar Series
Description
Opioid Response Network (ORN) - Hot Topics in Addiction Medicine - Spring 2022 Webinar Series

IMPORTANT: Be sure you complete all desired sessions PRIOR to completing the survey and claiming your certificate. You must claim your certifcate for us to report CME. 
Schedule

The Impact of Illicit Fentanyl Use on Opioid Use Disorder Treatment (Recorded on April 6, 2022)
     Andrew Huhn, PhD., M.B.A.

Case Studies and Q&A: The Impact of Illicit Fentanyl Use on Opioid Use Disorder Treatment (Recorded on April 13, 2022)
     Andrew Huhn, PhD., M.B.A.

Drugs, Stigma, and Health (Recorded on April 20, 2022)
     Robin A. Pollini, PhD MPH

Case Studies and Q&A: Drugs, Stigma, and Health ( Recorded on April 27, 2022)
     Robin A. Pollini, PhD MPH

The Fourth Wave: Addressing the Intertwined Fentanyl and Stimulant Overdose Crisis (Recorded on May 4, 2022)
     Daniel Ciccarone MD, MPH

Case Studies and Q&A: The Fourth Wave: Addressing the Intertwined Fentanyl and Stimulant Overdose Crisis (Recorded on May 11, 2022)
     Steven Shoptaw, MD, PhD

Speakers
Andrew Huhn, PhD., M.B.A.

My research is focused on understanding the human experience of opioid use and opioid use disorder (OUD). The majority of my work has been in human laboratory studies and clinical trials, and I have leveraged my background in psychology, neuroscience, and behavioral pharmacology to identify risk factors for illicit drug relapse and medication strategies to improve OUD treatment outcomes. These studies cover the continuum of care, including supervised opioid withdrawal and sustained recovery using medications for OUD. Topics of interest include sleep disturbance, drug craving, and diurnal measures of stress and mood. In addition, my work in OUD patients has naturally led me to investigate the tradeoffs between the abuse liability and analgesic efficacy of opioid medications, including research on persons with chronic and/or acute pain. My lab employs diverse methodological approaches to better understand opioid use and OUD, including neuroimaging, ecological momentary assessments, wearable technologies, human laboratory studies, and survey research. Taken together, this research is aimed at improving treatment outcomes directly and evaluating and strategizing macro-level changes to improve healthcare for substance use and related disorders. 
Robin Pollini, PhD, MPH

Dr. Pollini is a substance use and infectious disease epidemiologist whose research focuses on mitigating the adverse health impacts of injection drug use; these include overdose, HIV, viral hepatitis, and serious injection-related bacterial infections like endocarditis. She uses innovative mixed methods study designs to examine how individual- and structural-level factors influence drug-related morbidity and mortality as well as health services access and utilization among people who inject drugs. Dr. Pollini has been Principal Investigator of several grants funded by the National Institute on Drug Abuse (NIDA). 
Daniel Ciccarone, MD, MPH

Dr. Dan Ciccarone is the Justine Miner Professor in Addiction Medicine in the department of Family and Community Medicine at UCSF. He has been principal or co-investigator on numerous NIH sponsored public health research projects including his current Synthetics in Combination (SYNC) study. He is a recognized international scholar on the medical, public health and public policy dimensions of substance use, risks and consequences. He is Associate Editor for the International Journal of Drug Policy and recently edited an IJDP special issue on the ?triple wave crisis? of opioids, heroin and fentanyl in the US. He consults for numerous private and public entities including the ONDCP, CDC and FDA. 
Steven Shoptaw, PhD

Steven Shoptaw PhD is Professor in UCLA Departments of Family Medicine and Psychiatry and Biobehavioral Sciences and Professor (Hon) in Psychiatry at the University of Cape Town. Dr. Shoptaw energetically leads research, clinical and policy efforts to bring novel and high impact strategies to deliver culturally competent care and prevention for persons affected by addictions and HIV. He leads two research centers at UCLA on addiction medicine and infectious diseases and is Protocol Co-Chair for an HIV Prevention Trials Network study evaluating a Mobile Health Delivery Unit to Link Persons who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care. Mentoring emerging clinical and research scholars from diverse backgrounds is a strong passion. 
Julie Kmiec, DO, FAOAAM

Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific. She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA. She is currently an Associate Professor of Psychiatry at the University of Pittsburgh School of Medicine. She is board certified in general and addiction psychiatry. Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program and Bridge Clinic, as well as the Narcotic Addiction Treatment Program.
Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions. Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder. She is the Immediate Past President of the American Osteopathic Academy of Addiction Medicine. 
Summary
Availability: Retired
Cost: FREE
Credit Offered:
No Credit Offered
Contains: 7 Courses
Create Account
Recommended
Powered By